MedPath

Effect of Nitrate-rich Fruit and Vegetable Supplement on Blood Pressure

Not Applicable
Completed
Conditions
Flow Mediated Dilation
High Blood Pressure
Registration Number
NCT03486145
Lead Sponsor
Arizona State University
Brief Summary

It is hypothesized that the daily supplementation of a nitrate-rich, two-ounce fruit and vegetable energy supplement (Isagenix International LLC) by healthy young adults with a would increase circulating nitrates and improve cardiovascular parameters compared to a nitrate-deficient placebo (prune juice).

Detailed Description

Endothelial cells of the peripheral vasculature are key sources of vasoactive factors regulating healthy blood pressure. One of the primary vasodilatory factors released from these cells is nitric oxide (NO). Production of NO is stimulated both through enzymatic-dependent mechanisms via NO synthase, as well as from dietary intake of nitrate-containing foods or supplements that increase NO bioavailability. This study examined whether the daily consumption of a nitrate-rich, two-ounce fruit and vegetable energy supplement (Isagenix International LLC) would increase circulating nitrates and improve cardiovascular parameters compared to a nitrate-deficient placebo (prune juice). Healthy male adults aged 18-40y (n=45) were recruited to participate in this longitudinal double-blind, placebo-controlled, randomized clinical trial. Subjects maintained their typical diet and physical activity patterns during the study. Anthropometric and cardiovascular (blood pressure and flow-mediated dilation (FMD)) parameters, along with plasma nitrates and nitrites were measured at baseline and after one and two weeks of supplementation. Subjects also completed questionnaires on sleep quality and mood. It is hypothesized that the nitrate-rich FVS supplement will provide a good source of dietary nitrates and effectively reduced blood pressure in normotensive, healthy young males.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria

• healthy men aged 18-40y

Exclusion Criteria
  • hypo- or hypertension (blood pressure < 100/65 or >140/90
  • cigarette use within past year
  • food allergies
  • specific medication use (nitroglycerin, beta-blockers, calcium channel blockers),
  • unwillingness to drink juice concentrates and follow study restrictions.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Blood pressureTwo week change in blood pressure (week 2 - baseline)

The primary objective of this study was to examine the short-term effects of a novel, two-ounce nitrate-rich fruit and vegetable supplement (FVS) (AMPED NOx, Isagenix International LLC) on blood pressure in healthy young men.

Plasma nitrates and nitritesTwo week change in concentration (week 2 - baseline)

The primary objective of this study was to examine the short-term effects of a novel, two-ounce nitrate-rich fruit and vegetable supplement (FVS) (AMPED NOx, Isagenix International LLC) on plasma nitrates and nitrites in healthy young men.

Flow-mediated dilationTwo week change in dilation (week 2 - baseline)

The primary objective of this study was to examine the short-term effects of a novel, two-ounce nitrate-rich fruit and vegetable supplement (FVS) (AMPED NOx, Isagenix International LLC) on endothelial function in healthy young men.

Secondary Outcome Measures
NameTimeMethod
Effect of athletic status on blood pressureTwo week change in blood pressure (week 2 - baseline) by athletic status

To explore whether athletic status modified the blood pressure response to supplementation

Effect of athletic status on endothelial functionTwo week change in flow mediated dilation (week 2 - baseline) by athletic status

To explore whether athletic status modified the flow mediated dilation response to the supplement athletes

Trial Locations

Locations (1)

Arizona State University

🇺🇸

Phoenix, Arizona, United States

Arizona State University
🇺🇸Phoenix, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.